Responses
Clinical and epidemiological research
Extended report
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Compose a Response to This Article
Other responses
No responses have been published for this article.